特発性肺線維症の世界市場レポート 2024

特発性肺線維症の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には6.2%の年間複合成長率（CAGR）で52億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、研究開発努力の拡大、精密医療アプローチの採用、疾病発生率の増加、バイオマーカー開発の進歩、政府の取り組みと資金提供に起因すると考えられます。予測期間中に予想される注目すべき動向としては、診断技術の進歩、標的療法の出現、遠隔医療と遠隔モニタリングの成長、併用療法の利用、肺移植の進歩などが挙げられます。

特発性肺線維症市場は、主に線維性疾患の有病率の増加によって成長する準備ができています。さまざまな臓器における線維性結合組織の異常な蓄積を特徴とするこれらの症状は、線維症関連シグナル伝達経路を標的とする特発性肺線維症（IPF）薬剤による治療を受けます。特に、米国肺協会は2022年12月に、米国で約20万7,000人が罹患しており、毎年約5万8,000人が新たにIPFと診断されていると報告しました。この症状は男性に多く、主に50歳以上の人々に影響を及ぼしており、特発性肺線維症市場の推進において線維性疾患の拡大が重要な役割を果たしていることが強調されています。

特発性肺線維症市場の成長は、高齢者人口の増加によって促進されると予想されます。高齢者は加齢に伴う肺の構造や機能の変化により呼吸器疾患にかかりやすくなり、IPF治療の需要に貢献しています。 2022年 10月の世界貿易機関のデータによると、60歳以上の世界人口は2021年には10億人から14億人に増加しました。予測によると、世界の60歳以上の成人人口は2050年までに21億人に倍増します。 80歳以上の人は4億2,600万人に達すると予想されています。したがって、高齢者人口の増加は、特発性肺線維症市場の成長を促進する重要な要因を構成します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の特発性肺線維症市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ニンテダニブ
• ピルフェニドン
• その他
• 世界の特発性肺線維症市場、作用機序別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 抗線維化剤
• チロシンキナーゼ阻害剤
• その他
• 世界の特発性肺線維症市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 経口
• 非経口
• 世界の特発性肺線維症市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンラインプロバイダー
• 世界の特発性肺線維症市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院と診療所
• その他

第7章 地域および国の分析

• 世界の特発性肺線維症市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の特発性肺線維症市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 特発性肺線維症市場の競合情勢
• 特発性肺線維症市場の企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co. Inc.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC

第31章 その他の大手および革新的な企業

• Sanofi SA
• Gilead Sciences Inc.
• Toray Industries Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Biogen Inc.
• Sun Pharmaceutical Industries Limited
• Shionogi and Co. Ltd.
• Cipla Inc.
• Zydus Lifesciences Ltd.
• Chong Kun Dang Pharmaceutical Corp.
• Kyorin Pharmaceutical Co. Ltd.
• Galapagos NV
• Veracyte Inc.
• Genentech Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue surrounding the air sacs, known as alveoli, in the lungs. This condition results in the accumulation of scar tissue (fibrosis) within the lungs, hindering the efficient transfer of oxygen into the bloodstream.

The main types of drugs used in the treatment of idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, including idiopathic pulmonary fibrosis (IPF), which is an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. These drugs operate through various modes of action, such as antifibrotic agents and tyrosine kinase inhibitors, and can be administered through various routes, including oral and parenteral. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online platforms, serving various end users such as hospitals, clinics, and others.

The idiopathic pulmonary fibrosis market research report is one of a series of new reports from The Business Research Company that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89 billion in 2023 to $4.13 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The growth observed in the historical period can be attributed to factors such as the increasing aging population, limited treatment options, rising awareness of the disease, and the development of healthcare infrastructure.

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.24 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the forecast period can be attributed to expanded research and development efforts, the adoption of a precision medicine approach, a rise in disease incidence, advancements in biomarker development, and government initiatives and funding. Notable trends expected in the forecast period include advancements in diagnostic techniques, the emergence of targeted therapies, the growth of telemedicine and remote monitoring, the utilization of combination therapies, and advancements in lung transplantation.

The idiopathic pulmonary fibrosis market is poised for growth, primarily driven by the increasing prevalence of fibrotic diseases. These conditions, marked by the abnormal accumulation of fibrous connective tissue in various organs, receive treatment through idiopathic pulmonary fibrosis (IPF) drugs targeting fibrosis-related signaling pathways. Notably, the American Lung Association reported in December 2022 that around 207,000 individuals in the United States were affected, with approximately 58,000 new IPF cases diagnosed annually. This condition, more prevalent in men and predominantly affecting those aged over 50, underscores the significant role of escalating fibrotic diseases in driving the idiopathic pulmonary fibrosis market.

The growth of the idiopathic pulmonary fibrosis market is anticipated to be propelled by the increasing geriatric population. Elderly individuals, more susceptible to respiratory diseases due to age-related changes in lung structure and function, contribute to the demand for IPF treatments. According to data from the World Trade Organization in October 2022, the global population aged 60 and above increased from 1 billion to 1.4 billion in 2021. Projections suggest a doubling of the world's population of adults aged 60 and above to 2.1 billion by 2050, with those aged 80 or more expected to reach 426 million. Thus, the rising geriatric population constitutes a significant factor driving the growth of the idiopathic pulmonary fibrosis market.

A notable trend gaining momentum in the idiopathic pulmonary fibrosis market is product innovation. Major companies in the industry are placing emphasis on developing innovative products to strengthen their market positions and gain a competitive advantage. For instance, in May 2022, Sandoz, a Swiss-based pharmaceutical company, introduced a generic version of pirfenidone, the first AB-rated equivalent to Genentech's Esbriet, for treating idiopathic pulmonary fibrosis. This generic medication, accessible through specialty pharmacies, offers eligible patients the benefit of a USD 0 co-pay program.

Companies in the idiopathic pulmonary fibrosis market are directing their efforts toward innovative products such as anti-fibrotic small-molecule inhibitors to sustain their market positions. These inhibitors, designed to target and inhibit fibrotic processes in the body, represent a significant advancement. In June 2023, Insilico Medicine, a US-based biotechnology company, initiated Phase II clinical trials for INS018_055, the world's first anti-fibrotic small molecule inhibitor designed through generative artificial intelligence. This groundbreaking approach utilizing AI in drug discovery showcases the potential for progress in idiopathic pulmonary fibrosis treatment.

In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based biotechnology company specializing in the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. This acquisition aims to enhance AbbVie's antibody research capabilities and expand its immunology portfolio.

Major companies operating in the idiopathic pulmonary fibrosis market report are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

North America was the largest region in the idiopathic pulmonary fibrosis market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Idiopathic Pulmonary Fibrosis Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on idiopathic pulmonary fibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for idiopathic pulmonary fibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic pulmonary fibrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types
• 2) By Mode Of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes of Action
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers
• 5) By End Users: Hospitals and Clinics; Other End Users
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Idiopathic Pulmonary Fibrosis Market Characteristics

3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies

4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Idiopathic Pulmonary Fibrosis Market Size and Growth

• 5.1. Global Idiopathic Pulmonary Fibrosis Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Idiopathic Pulmonary Fibrosis Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Idiopathic Pulmonary Fibrosis Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Idiopathic Pulmonary Fibrosis Market Segmentation

• 6.1. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Nintedanib
• Pirfenidone
• Other Drug Types
• 6.2. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Other Modes of Action
• 6.3. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• 6.4. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Providers
• 6.5. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals and Clinics
• Other End Users

7. Idiopathic Pulmonary Fibrosis Market Regional And Country Analysis

• 7.1. Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

• 8.1. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Idiopathic Pulmonary Fibrosis Market

• 9.1. China Idiopathic Pulmonary Fibrosis Market Overview
• 9.2. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Idiopathic Pulmonary Fibrosis Market

• 10.1. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Idiopathic Pulmonary Fibrosis Market

• 11.1. Japan Idiopathic Pulmonary Fibrosis Market Overview
• 11.2. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Idiopathic Pulmonary Fibrosis Market

• 12.1. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Idiopathic Pulmonary Fibrosis Market

• 13.1. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Idiopathic Pulmonary Fibrosis Market

• 14.1. South Korea Idiopathic Pulmonary Fibrosis Market Overview
• 14.2. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Idiopathic Pulmonary Fibrosis Market

• 15.1. Western Europe Idiopathic Pulmonary Fibrosis Market Overview
• 15.2. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Idiopathic Pulmonary Fibrosis Market

• 16.1. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Idiopathic Pulmonary Fibrosis Market

• 17.1. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Idiopathic Pulmonary Fibrosis Market

• 18.1. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Idiopathic Pulmonary Fibrosis Market

• 19.1. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Idiopathic Pulmonary Fibrosis Market

• 20.1. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Idiopathic Pulmonary Fibrosis Market

• 21.1. Eastern Europe Idiopathic Pulmonary Fibrosis Market Overview
• 21.2. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Idiopathic Pulmonary Fibrosis Market

• 22.1. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Idiopathic Pulmonary Fibrosis Market

• 23.1. North America Idiopathic Pulmonary Fibrosis Market Overview
• 23.2. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Idiopathic Pulmonary Fibrosis Market

• 24.1. USA Idiopathic Pulmonary Fibrosis Market Overview
• 24.2. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Idiopathic Pulmonary Fibrosis Market

• 25.1. Canada Idiopathic Pulmonary Fibrosis Market Overview
• 25.2. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Idiopathic Pulmonary Fibrosis Market

• 26.1. South America Idiopathic Pulmonary Fibrosis Market Overview
• 26.2. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Idiopathic Pulmonary Fibrosis Market

• 27.1. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Idiopathic Pulmonary Fibrosis Market

• 28.1. Middle East Idiopathic Pulmonary Fibrosis Market Overview
• 28.2. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Idiopathic Pulmonary Fibrosis Market

• 29.1. Africa Idiopathic Pulmonary Fibrosis Market Overview
• 29.2. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles

• 30.1. Idiopathic Pulmonary Fibrosis Market Competitive Landscape
• 30.2. Idiopathic Pulmonary Fibrosis Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck & Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bristol-Myers Squibb Company
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AstraZeneca PLC
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Idiopathic Pulmonary Fibrosis Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Gilead Sciences Inc.
• 31.3. Toray Industries Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Viatris Inc.
• 31.6. Biogen Inc.
• 31.7. Sun Pharmaceutical Industries Limited
• 31.8. Shionogi and Co. Ltd.
• 31.9. Cipla Inc.
• 31.10. Zydus Lifesciences Ltd.
• 31.11. Chong Kun Dang Pharmaceutical Corp.
• 31.12. Kyorin Pharmaceutical Co. Ltd.
• 31.13. Galapagos NV
• 31.14. Veracyte Inc.
• 31.15. Genentech Inc.

32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking

33. Global Idiopathic Pulmonary Fibrosis Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market

35. Idiopathic Pulmonary Fibrosis Market Future Outlook and Potential Analysis

• 35.1 Idiopathic Pulmonary Fibrosis Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Idiopathic Pulmonary Fibrosis Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Idiopathic Pulmonary Fibrosis Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer